IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
91 hedge funds and large institutions have $1.08B invested in IGM Biosciences in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 24 increasing their positions, 35 reducing their positions, and 7 closing their positions.
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
12% more funds holding
Funds holding: 81 → 91 (+10)
6% more capital invested
Capital invested by funds: $1.02B → $1.08B (+$59.1M)
2.64% more ownership
Funds ownership: 57.9% → 60.54% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less call options, than puts
Call options by funds: $39.7M | Put options by funds: $43.6M
31% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$40.8M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$16.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.7M |
| 4 |
Alkeon Capital Management
New York
|
+$10.4M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$5.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.47M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.82M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.92M |
| 5 |
BlackRock
New York
|
-$5.91M |
IGMS Hedge Fund Activity: Q3 2020 in Review
91 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q3 2020, worth a combined $1.08B — up 5.8% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new IGMS positions and 7 closed out — a net gain of 10 holders — while 24 added to existing stakes and 35 trimmed.
The largest buyer was Artal Group, opening a new position worth an estimated $40.8M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $8.47M sold.
- 91 institutional investors held IGM Biosciences (IGMS) as of Q3 2020, up from 81 in Q2 2020.
- Funds reported $1.08B of IGM Biosciences stock for Q3 2020, up 5.8% quarter-over-quarter.
- 17 funds opened new IGM Biosciences positions in Q3 2020 and 7 closed out, a net change of +10 holders.
- The largest IGM Biosciences buyer in Q3 2020 was Artal Group, an estimated $40.8M added.
- The largest IGM Biosciences seller in Q3 2020 was PFM Health Sciences, an estimated $8.47M sold.
Based on aggregated 13F filings for Q3 2020.